Generic Qoliana Availability
Last updated on Jan 11, 2023.
Qoliana is a brand name of brimonidine ophthalmic, approved by the FDA in the following formulation(s):
QOLIANA (brimonidine tartrate - solution/drops;ophthalmic)
Has a generic version of Qoliana been approved?
A generic version of Qoliana has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Qoliana and have been approved by the FDA:
Approval date: January 31, 2022
Strength(s): 0.15% [AT]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Qoliana. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Topical brimonidine tartrate formulations that lack chlorine dioxide
Issued: September 4, 2007
Inventor(s): Espino; Ramon L. & Bhagat; Haresh G.
Assignee(s): Alcon, Inc.
Topical solution compositions of brimonidine tartrate are disclosed. The solution compositions lack an oxidative preservative.
Patent expiration dates:
- August 19, 2025✓
- August 19, 2025
More about Qoliana (brimonidine ophthalmic)
- Check interactions
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: ophthalmic glaucoma agents
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
|AT||Topical products. There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of in vivo bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded AT. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded AB when supported by adequate bioequivalence data, and BT in the absence of such data.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.